Most U.S. Pharmas Don't Pay Any U.S. Income Tax
Gilead Sciences, Inc.'s (NASDAQ:GILD) One-year Returns Climbed After Last Week's 6.1% Gain, Institutional Investors Must Be Happy
Gilead Sciences Options Spot-On: On July 26th, 72,710 Contracts Were Traded, With 296.52K Open Interest
10 Health Care Stocks Whale Activity In Today's Session
Unusual Options Activity: GILD, COIN and Others Attract Market Bets, GILD V/OI Ratio Reaches 67.0
Analysts' Opinions Are Mixed on These Healthcare Stocks: Align Tech (ALGN) and Gilead Sciences (GILD)
Hold Rating on Gilead Sciences Amidst Q2 Revenue Shortfall and Competitive Pressures
Express News | Gilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
Gilead Science Stock (NASDAQ:GILD): The Path to a $105 Price Target
This Is What Whales Are Betting On Gilead Sciences
Express News | Gilead Sciences Shares Are Trading Higher After the Company Announced New 5-year Data Reinforcing Biktarvy as a Long Term HIV Treatment
Express News | Gilead Sciences Presents New 5-Year Data Reinforcing Biktarvy As Long-Term HIV Treatment; Investigational Dosing Frequencies Aim To Expand Options And Address Unmet Needs; Key Findings Presented At AIDS 2024 Conference Highlight Innovative HIV...
Express News | Gilead Sciences Inc - Biktarvy Well Tolerated in Hispanic/Latine People With Hiv
Express News | Gilead Presents Research Data Across Its Broad and Innovative Hiv Treatment Portfolio and Pipeline
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $85
Barclays Maintains Gilead Sciences(GILD.US) With Hold Rating, Maintains Target Price $76
Analysts' Opinions Are Mixed on These Healthcare Stocks: Healthequity (HQY), Community Health (CYH) and Gilead Sciences (GILD)
Gilead's $42.5K Priced HIV Drug Could Be Made At Just $40 Annually, Campaigners Urge Company To Slash Price
Gilead Sciences Says Lenacapavir 'Highly Effective' in HIV Prevention in Phase 3 Study
Express News | Gilead Sciences Announced Phase 3 Purpose 1 Trial Data, Showing Zero Infections And 100% Efficacy And Superiority Of Lenacapavir To Background HIV Incidence For The Investigational Use Of HIV Prevention In Cisgender Women